Inhibitory Effects of Glycoprotein IIb/IIIa Antagonists and Aspirin on the Release of Soluble CD40 Ligand During Platelet Stimulation

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Circulation

• Publication date

  2003-03-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.0000053559.46158.ADPMID 12615789
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Platelets in Thrombotic and Nonthrombotic Disorders – Pathophysiology, Pharmacology and Therapeutics

  2003cited by this paper
• Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis.

  2002cited by this paper
• CD40 Ligand Inhibits Endothelial Cell Migration by Increasing Production of Endothelial Reactive Oxygen Species

  2002cited by this paper
• Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization.

  2002cited by this paper
• CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism

  2002cited by this paper
• Cardiopulmonary Bypass Induces Release of Soluble CD40 Ligand

  2002cited by this paper
• The CD40/CD154 receptor/ligand dyadRID="†"ID="†" Review

  2001cited by this paper
• Identification of the platelet ADP receptor targeted by antithrombotic drugs

  2001cited by this paper
• Inflammatory role of platelets in acute coronary syndromes

  2001cited by this paper
• Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease

  2001cited by this paper
• The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40.

  2001cited by this paper
• Eptifibatide in Percutaneous Coronary Intervention: The ESPRIT Trial Results.

  2001cited by this paper
• Soluble CD40L and Cardiovascular Risk in Women

  2001cited by this paper
• Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets

  2001cited by this paper
• Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization

  2001cited by this paper
• Platelet CD40 ligand (CD40L) – subcellular localization, regulation of expression, and inhibition by clopidogrel

  2001cited by this paper
• Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists.

  2001cited by this paper
• Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.

  2000cited by this paper
• Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.

  2000cited by this paper
• Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease.

  2000cited by this paper
• Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice.

  2000cited by this paper
• Requirement for CD154 in the progression of atherosclerosis

  1999cited by this paper
• T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation.

  1999cited by this paper
• Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes.

  1999cited by this paper
• Reduction of atherosclerosis in mice by inhibition of CD40 signalling

  1998cited by this paper
• Activated Platelets Induce Tissue Factor Expression on Human Umbilical Vein Endothelial Cells by Ligation of CD40

  1998cited by this paper
• CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

  1998cited by this paper
• A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells

  1997cited by this paper
• Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade With Percutaneous Coronary Intervention

  1997cited by this paper
• Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.

  1997cited by this paper
• Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis.

  1997cited by this paper
• Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate.

  1997cited by this paper
• A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells.

  1997cited by this paper
• Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3

  1996cited by this paper
• Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3.

  1996cited by this paper
• Activation of human monocytes through CD40 induces matrix metalloproteinases.

  1996cited by this paper
• Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes.

  1995cited by this paper
• Expression of functional CD40 by vascular endothelial cells

  1995cited by this paper
• Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri.

  1991cited by this paper
• Role of thromboxane A2 as a mediator of platelet-activating-factor-induced aggregation of human platelets.

  1989cited by this paper

• The impact of platelets and antiplatelets medications on immune mediation

  2024cites this paper
• An Updated Review on Glycoprotein IIb/IIIa Inhibitors as Antiplatelet Agents: Basic and Clinical Perspectives

  2023cites this paper
• Blood Platelets in Infection: The Multiple Roles of the Platelet Signalling Machinery

  2023cites this paper
• Aortic aneurysms and markers of platelet activation, hemostasis, and endothelial disruption in people living with HIV

  2023cites this paper
• Novel Functions of Integrins as Receptors of CD154: Their Role in Inflammation and Apoptosis

  2022cites this paper
• 3,4-Methylenedioxy-β-Nitrostyrene Alleviates Dextran Sulfate Sodium–Induced Mouse Colitis by Inhibiting the NLRP3 Inflammasome

  2022cites this paper
• Platelet Inhibition by Low-Dose Acetylsalicylic Acid Reduces Neuroinflammation in an Animal Model of Multiple Sclerosis

  2021cites this paper
• Aspirin Reduces the Potentiating Effect of CD40L on Platelet Aggregation via Inhibition of Myosin Light Chain

  2020cites this paper
• Systemic Inflammatory Response Syndrome After Surgery: Mechanisms and Protection

  2020cites this paper
• Antiplatelet agents'-ticagrelol and eptifibatide-safety in experimental colitis in mice.

  2020cites this paper
• Platelet Function and Coronary Microvascular Dysfunction

  2019cites this paper
• The Role of Platelets in Diabetes Mellitus

  2019cites this paper
• High serum sCD40L during the first week of malignant middle cerebral artery infarction and mortality.

  2019cites this paper
• Expression of Blood Cells Associated CD Markers and Cardiovascular Diseases: Clinical Applications in Prognosis.

  2019cites this paper
• Thromboinflammatory Functions of Platelets in Ischemia–Reperfusion Injury and Its Dysregulation in Diabetes

  2018cites this paper
• Novel biomarkers of cardiovascular disease: Applications in clinical practice

  2018cites this paper
• Prognostic evaluation of soluble CD40L in acute myocardial infarction: is not fancy, is science!

  2017cites this paper
• Integrin signaling in atherosclerosis

  2017cites this paper
• Plaquettes sanguines et insuffisance rénale aiguë : rôle du couple CD154/CD40 dans la constitution des lésions tubulaires

  2017cites this paper
• Elevated levels of soluble CD40 ligand are associated with antiphospholipid antibodies in patients with systemic lupus erythematosus.

  2017cites this paper
• Structural and functional characterisation of dioxolane A3, a new eicosanoid generated by cycooxygenase-1 in platelets

  2016cites this paper
• latelets , the ardiologist , and oronary Artery Disease : oving Beyond Aggregation

  2016cites this paper
• P hromboxane-Dependent CD 40 igand Release in Type 2 Diabetes Mellitus

  2016cites this paper
• The Effects of Antiplatelet, Antithrombotic, and Thrombolytic Agents on Inflammation and Circulating Inflammatory Biomarkers

  2016cites this paper
• Management of Raynaud Phenomenon and Digital Ulcers in Scleroderma.

  2015cites this paper
• Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD

  2015cites this paper
• Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes

  2015cites this paper
• New frontiers for platelet CD154

  2015cites this paper
• The Versatile Platelet in Critical Illness

  2015cites this paper
• Soluble CD40 ligand contributes to dendritic cell-mediated T-cell dysfunction in HIV-1 infection

  2015cites this paper
• Platelet JAM-A in vascular Inflammation and remodeling

  2015cites this paper
• Tyrosine kinase inhibitors modulate platelet function in vitro, ex vivo and in vivo

  2015cites this paper
• Platelets in Inflammation and Atherogenesis

  2015cites this paper
• An effect of glycoprotein IIb/IIIa inhibitors on the kinetics of red blood cells aggregation

  2014cites this paper
• Potential Role of Soluble CD40 Ligand as Inflammatory Biomarker in Colorectal Cancer Patients

  2014cites this paper
• The Signaling Role of CD40 Ligand in Platelet Biology and in Platelet Component Transfusion

  2014cites this paper
• COMPARISON OF SCD40L LEVELS IN PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM BEFORE AND AFTER LEVOTHYROXINE TREATMENT SUBKLİNİK HİPOTROİDİLİ HASTALARDA LEVOTİROKSİN TEDAVİSİ ÖNCESİ VE SONRASI SCD40L DÜZEYLERİNİN KARŞILAŞTIRILMASI

  2014cites this paper
• Multipotent role of platelets in inflammatory bowel diseases: a clinical approach.

  2014cites this paper
• Chapter 35 – Diabetes Mellitus

  2013cites this paper
• Plaquettes sanguines et entretien de l’inflammation post-infectieuse

  2013cites this paper
• Morphology of platelet Golgi apparatus and their significance after acute cerebral infarction

  2013cites this paper
• Targeting platelet-derived soluble CD40 ligand: a new treatment strategy for HIV-associated neuroinflammation?

  2013cites this paper
• Impact of selective infarct-related artery infusion of tirofiban on myocardial reperfusion and bleeding complications in patients with acute myocardial infarction: the SUIT-AMI trial.

  2013cites this paper
• Soluble CD40 ligand release in patients with stable coronary artery disease during elective stent implantation: effect of drug-eluting stent over bare metal stent.

  2013cites this paper
• A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease.

  2012cites this paper
• Assessment of acute coronary syndromes: focus on novel biomarkers.

  2012cites this paper
• Traditional and Novel Risk Factors in Atherothrombosis

  2012cites this paper
• CD40 Ligand and Its Receptors in Atherothrombosis

  2012cites this paper
• Reconstituted HDL in acute coronary syndromes.

  2012cites this paper
• Eptifibatide

  2012cites this paper
• Cell adhesion molecules as pharmaceutical target in atherosclerosis.

  2012cites this paper
• Interaction with damaged vessel wall in vivo in humans induces platelets to express CD40L resulting in endothelial activation with no effect of aspirin intake.

  2011cites this paper
• The CD40-CD40L system in cardiovascular disease

  2011cites this paper
• Beyond Thrombosis

  2011cites this paper
• Platelet activation in patients with atherosclerotic renal artery stenosis undergoing stent revascularization.

  2011cites this paper
• Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions

  2011cites this paper
• Percutaneous treatment of complex lesions and complex patients

  2011cites this paper
• Estudio de los niveles de ligando CD40 en pacientes con síndrome coronario agudo

  2011cites this paper
• The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.

  2010cites this paper
• Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy).

  2010cites this paper
• Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy

  2010cites this paper
• Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions.

  2010cites this paper
• CD40 ligand shedding is regulated by interaction between matrix metalloproteinase‐2 and platelet integrin αIIbβ3

  2010cites this paper
• Rôle fonctionnel du Toll-Like Receptor 4 exprimé par les plaquettes sanguines en tant que cellules inflammatoires de l'immunité

  2010cites this paper
• Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome.

  2010cites this paper
• Effect of High Bolus Dose Tirofiban on the Inflammatory Response Following Percutaneous Coronary Intervention

  2010cites this paper
• Regulation of CD40L (CD154) and CD62P (p-selectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients.

  2010cites this paper
• Measuring the right compound at the right time is not always easy.

  2010cites this paper
• Thromboxane A(2) promotes soluble CD40 ligand release from human platelets.

  2010cites this paper
• When working towards an optimised carotid stenting procedure does patient, procedural and pharmacological selection impact on outcome?

  2010cites this paper
• From atherosclerosis to acute coronary syndromes: the role of soluble CD40 ligand.

  2010cites this paper
• Aspirin resistance following pediatric cardiac surgery.

  2010cites this paper
• Plasma concentrations of soluble CD40 ligand in smokers with acute myocardial infarction: a pilot study

  2010cites this paper
• A review of antiplatelet drugs, coronary artery diseases and cardiopulmonary bypass.

  2010cites this paper
• Inflammatory response to percutaneous coronary intervention in stable coronary artery disease

  2010influential citation
• Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention--effects on soluble CD40 ligand concentrations.

  2009cites this paper
• A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation.

  2009cites this paper
• The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?

  2009cites this paper
• Platelet Physiology and the Role of the Platelet in Ischemic Heart Disease

  2009cites this paper
• Inflammation, thrombosis and endothelial dysfunction in myocardial infarction

  2009cites this paper
• Platelets play important roles in the late phase of the immediate hypersensitivity reaction.

  2009cites this paper
• Eptifibatide does not suppress the increase of inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome

  2009cites this paper
• Preliminary evidence for a matrix metalloproteinase-2 (MMP-2)-dependent shedding of soluble CD40 ligand (sCD40L) from activated platelets

  2009cites this paper
• Linking Inflammation With Atherothrombosis

  2009cites this paper
• The CD40/CD40 ligand system: linking inflammation with atherothrombosis.

  2009cites this paper
• Antithrombin III suppresses ADP-induced platelet granule secretion: inhibition of HSP27 phosphorylation.

  2009cites this paper
• Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study

  2009cites this paper
• Relationship between the serum sCD40L level and aspirin-resistant platelet aggregation in patients with stable coronary artery disease.

  2008cites this paper
• CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease.

  2008cites this paper
• Variability of response to antiplatelet therapy

  2008cites this paper
• Immunopathogenic mechanisms of Coronary Artery Disease and plaque destabilization

  2008cites this paper
• Future innovations in anti‐platelet therapies

  2008cites this paper
• The pathogenic role of tumor necrosis factor superfamily ligands in atherogenesis and plaque destabilization

  2008cites this paper
• [Investigation of gene expression profiles in patients with blood stasis syndrome].

  2008cites this paper
• Platelet pro-aggregatory effects of CD40L monoclonal antibody.

  2008cites this paper
• Enhanced plasma levels of LIGHT in patients with acute atherothrombotic stroke

  2008cites this paper
• Soluble CD40 ligand and atrial fibrillation: relationship to platelet activation, and endothelial damage/dysfunction.

  2008cites this paper
• Effects of Coronary Prestenting Platelet Inhibition on Coronary Poststenting Inflammation

  2008cites this paper
• Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation: relationship to soluble P-selectin, stroke risk factors, and risk factor intervention.

  2008cites this paper
• CD40/CD40L system and vascular disease

  2007influential citation